Quantbot Technologies LP Sells 121,439 Shares of GSK plc (NYSE:GSK)

Quantbot Technologies LP decreased its holdings in shares of GSK plc (NYSE:GSK) by 57.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 89,371 shares of the pharmaceutical company’s stock after selling 121,439 shares during the period. Quantbot Technologies LP’s holdings in GSK were worth $3,023,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Lee Danner & Bass Inc. bought a new stake in shares of GSK during the 4th quarter valued at $39,000. Whittier Trust Co. of Nevada Inc. raised its position in shares of GSK by 23.0% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 2,233 shares of the pharmaceutical company’s stock valued at $75,000 after acquiring an additional 417 shares during the last quarter. Whittier Trust Co. raised its position in shares of GSK by 133.7% during the 4th quarter. Whittier Trust Co. now owns 38,150 shares of the pharmaceutical company’s stock valued at $1,290,000 after acquiring an additional 21,826 shares during the last quarter. GM Advisory Group LLC raised its position in shares of GSK by 19.3% during the 4th quarter. GM Advisory Group LLC now owns 8,035 shares of the pharmaceutical company’s stock valued at $272,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Koss Olinger Consulting LLC raised its position in shares of GSK by 8.9% during the 4th quarter. Koss Olinger Consulting LLC now owns 67,969 shares of the pharmaceutical company’s stock valued at $2,299,000 after acquiring an additional 5,583 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $39.22 on Friday. The firm has a market cap of $81.18 billion, a PE ratio of 24.67, a PEG ratio of 1.12 and a beta of 0.58. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a fifty day moving average price of $36.66 and a 200 day moving average price of $36.92.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.01%. GSK’s dividend payout ratio is presently 98.74%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GSK. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.